Overview

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Status:
Recruiting

Trial end date:
2022-11-26

Target enrollment:

Participant gender:

Summary

This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL.

Phase:

Phase 2

Details

Lead Sponsor:

Allergan

Treatments:

abobotulinumtoxinA
Botulinum Toxins, Type A